Establishment Labs Holdings Inc. $ESTA Shares Bought by Mudita Advisors LLP

Key Points

• Mudita Advisors LLP increased its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 15.6%, owning 479,359 shares valued at approximately $19.56 million.
• Analysts have mixed opinions on ESTA, with Citigroup and Mizuho raising price targets to $47.00 and $70.00 respectively, while Wall Street Zen downgraded it from a "hold" to a "sell" rating.
• For the latest quarter, Establishment Labs reported an earnings miss with a loss of ($0.57) per share, despite revenue increasing by 16.1% year-over-year to $51.30 million.

Mudita Advisors LLP boosted its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 15.6% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 479,359 shares of the company's stock after acquiring an additional 64,859 shares during the quarter. Establishment Labs comprises about 9.9% of Mudita Advisors LLP's portfolio, making the stock its 4th largest position. Mudita Advisors LLP owned about 1.66% of Establishment Labs worth $19,560,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ESTA. ANTIPODES PARTNERS Ltd acquired a new stake in Establishment Labs during the 1st quarter worth about $81,000. Elevation Point Wealth Partners LLC purchased a new position in shares of Establishment Labs during the 1st quarter valued at about $207,000. Patriot Financial Group Insurance Agency LLC purchased a new position in shares of Establishment Labs during the 1st quarter valued at about $234,000. ADAR1 Capital Management LLC acquired a new position in Establishment Labs in the 1st quarter worth about $326,000. Finally, New York State Common Retirement Fund acquired a new position in Establishment Labs in the 1st quarter worth about $894,000. Institutional investors and hedge funds own 72.91% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ESTA. Citigroup upped their price target on Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a report on Wednesday, July 9th. Mizuho upped their price target on Establishment Labs from $58.00 to $70.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. BTIG Research assumed coverage on Establishment Labs in a research note on Friday, May 16th. They set a "buy" rating and a $62.00 price objective for the company. Canaccord Genuity Group assumed coverage on Establishment Labs in a research note on Wednesday, August 20th. They set a "buy" rating and a $60.00 price objective for the company. Finally, Wall Street Zen lowered Establishment Labs from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Establishment Labs presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.50.

Establishment Labs Stock Up 2.5%

NASDAQ:ESTA opened at $39.21 on Wednesday. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 9.71. The stock's fifty day moving average is $41.23 and its two-hundred day moving average is $37.98. Establishment Labs Holdings Inc. has a 52 week low of $26.56 and a 52 week high of $50.85. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -12.86 and a beta of 0.85.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). The company had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The firm's revenue was up 16.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.62) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. Research analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.